Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.44 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23640202 | 1.00 | CRBN (0.44) | CRBNDDB1GSPT1BCHEACHE | |
| SCHEMBL23639958 | 1.00 | CRBN (0.44) | CRBNDDB1GSPT1BCHEACHE | |
| SCHEMBL24302582 | 0.89 | NPC1 (0.43) | CRBNDDB1HTR1AADRA2ADRD2 | |
| SCHEMBL24302800 | 0.89 | NPC1 (0.43) | CRBNDDB1HTR1AADRA2ADRD2 | |
| SCHEMBL24302796 | 0.89 | NPC1 (0.43) | CRBNDDB1HTR1AADRA2ADRD2 | |
| SCHEMBL24303027 | 0.88 | DDB1 (0.42) | CRBNDDB1 | |
| SCHEMBL24302281 | 0.88 | DDB1 (0.42) | CRBNDDB1 | |
| SCHEMBL24303033 | 0.88 | DDB1 (0.42) | CRBNDDB1 | |
| SCHEMBL24754154 | 0.87 | ALDH1A1 (0.42) | CRBNDDB1GSPT1 | |
| SCHEMBL23640450 | 0.85 | DDB1 (0.40) | CRBNDDB1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3848367-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CRBN, CSNK2A1, CSNK2A2 | CRBN 1/4885DDB1 333/4885GSPT1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.